| 22 2.63 (13.58%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.17  |
1-year : | 30.57 |
| Resists | First : | 22.4 |
Second : | 26.17 |
| Pivot price | 18.61 |
|||
| Supports | First : | 17.89 |
Second : | 15.1 |
| MAs | MA(5) : | 19.07 |
MA(20) : | 18.24 |
| MA(100) : | 21.47 |
MA(250) : | 239.65 |
|
| MACD | MACD : | 0 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 66.4 |
D(3) : | 51.2 |
| RSI | RSI(14): 67.1 |
|||
| 52-week | High : | 910 | Low : | 15.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ QNCX ] has closed above the upper band by 26.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 110 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.45 - 22.56 | 22.56 - 22.65 |
| Low: | 18.2 - 18.31 | 18.31 - 18.4 |
| Close: | 21.8 - 22 | 22 - 22.18 |
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Wed, 29 Jul 2026
Oppenheimer Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $82 - Moomoo
Sat, 25 Jul 2026
Quince Therapeutics Inc (QNCX) Institutional Confidence - tradingkey.com
Fri, 24 Jul 2026
Quince Therapeutics, Inc. Revenue Breakdown – NASDAQ:QNCX - TradingView
Fri, 24 Jul 2026
Quince Therapeutics Inc (QNCX) Cash Flow - tradingkey.com
Thu, 11 Jun 2026
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Tue, 02 Jun 2026
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 14.1 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 101 (K) |
| EPS | -210 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.5 % |
| Return on Equity (ttm) | -192.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -49.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|